LOXO-NGR-21001 (NCT05241834) is a global (currently recruiting in the US), open-label, first-in-human phase I study of LOXO-260 in patients with RET fusion–positive advanced solid tumors and RET-mutant MTC who received a prior SRI and other solid tumors with RET alterations refractory to SRI [48]. Here, RET is linked to medullary thyroid gland carcinoma.